Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Blood Tests for Alzheimer's Disease: Can Plasma Biomarkers Diagnose and Predict Disease Progression (BLAD)

16 juli 2026 bijgewerkt door: Prof. Massimo Filippi, IRCCS San Raffaele

The Diagnostic and Prognostic Role of Plasma Biomarkers in Alzheimer's Disease

BLAD is a prospective, monocentric, observational epidemiological study with an additional procedure (annual blood draw) evaluating the diagnostic and prognostic performance of plasma biomarkers for Alzheimer's disease (AD) in a large cohort of patients attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital, Milan, Italy.

2000 patients will be enrolled and followed annually for 5 years. A validation sub-study (150 patients) will compare plasma biomarkers against CSF biomarkers as the gold standard.

The study aims to establish plasma biomarkers as a less invasive and more cost-effective alternative to CSF analysis and amyloid-PET for the diagnosis and prognosis of AD.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

In light of the possible advent of disease-modifying drugs for Alzheimer's disease (AD), reliable biomarkers have been developed in recent years to define the presence of AD pathology at the brain level. The current biological gold standards are cerebrospinal fluid (CSF) biomarkers (CSF-Abeta40, CSF-Abeta42, CSF-pTau, CSF-NfL) and amyloid-PET. Both methods have excellent diagnostic properties but are costly and invasive, limiting their use outside of highly specialized centers.

Plasma biomarkers (plasma-Abeta40, plasma-Abeta42, plasma-pTau-181, plasma-NfL, plasma-ApoE, plasma-ApoE4, plasma-GFAP, plasma-sTREM2, and other plasma neurodegeneration biomarkers) represent a potentially less invasive and more economically accessible alternative. Recent studies have shown that plasma biomarkers can differentiate AD from other neurodegenerative disorders with accuracy comparable to CSF and PET, detect AD pathology in MCI patients, and predict future development of AD dementia in patients with SCD or MCI. However, more research is needed before their widespread use in clinical practice.

The BLAD study is designed as a monocentric, prospective, observational epidemiological study with an additional procedure (annual blood draw for 5 years) and a diagnostic accuracy sub-study (not device-based).

Patients will be recruited among those attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital during routine clinical practice. All enrolled patients will undergo annual blood sampling for 5 years in addition to standard clinical assessments.

A sub-population of 150 patients who undergo lumbar puncture as part of their routine diagnostic workup will enter the validation sub-study. Only those whose CSF biomarkers confirm a biological diagnosis of Alzheimer's disease will continue follow-up; others will exit the sub-study.

The equipment for plasma biomarker measurement (CE-marked medical device) and laboratory kits will be provided on free loan by Fujirebio. No clinical or laboratory data will be shared with Fujirebio.

Statistical analyses will include: log-rank test to compare time to AD development between groups above and below the biomarker threshold; linear stepwise regression models, linear mixed-effects models, and multivariable Cox models to assess the prognostic value of plasma biomarkers; longitudinal generalized linear models for repeated measures or Wilcoxon test to assess biomarker dynamics over time. For the validation sub-study, ROC curve analysis will be performed to assess accuracy, sensitivity, and specificity of plasma biomarkers against CSF gold standard.

Studietype

Observationeel

Inschrijving (Geschat)

2000

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

  • Naam: Giuseppe Magnani, MD

Studie Locaties

    • Milano
      • Milan, Milano, Italië, 20132
        • Werving
        • IRCCS Ospedale San Raffaele - Cognitive Disorders and Dementia Center (CDCD)
        • Contact:
        • Contact:
          • Giuseppe Magnani, MD
        • Hoofdonderzoeker:
          • Massimo Filippi, Prof, MD
        • Onderonderzoeker:
          • Federica Agosta, MD
        • Onderonderzoeker:
          • Giuseppe Magnani, MD
        • Onderonderzoeker:
          • Giordano Cecchetti, MD
        • Onderonderzoeker:
          • Francesca Caso, MD
        • Onderonderzoeker:
          • Roberto Santangelo, MD
        • Onderonderzoeker:
          • Gioele Spinelli, MD
        • Onderonderzoeker:
          • Giulia Rugarli, MD
        • Onderonderzoeker:
          • Federico Coraglia, MD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Adult patients attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital, Milan, Italy, presenting with subjective or objective cognitive complaints of progressive and suspected neurodegenerative nature.

Beschrijving

Inclusion Criteria (main study and sub-study):

  1. Age greater than or equal to 40 years (patients of childbearing age are admitted).
  2. Subjective or objective cognitive complaints, progressive in nature and of suspected neurodegenerative origin.
  3. Mini-Mental State Examination (MMSE) score greater than or equal to 18.

    Additional inclusion criterion for the validation sub-study:

  4. Availability of CSF biomarkers for Alzheimer's disease within 6 months of the blood draw.

Exclusion Criteria (main study):

  1. Secondary forms of cognitive impairment based on medical history, neurological examination, and neuroimaging findings.
  2. Pregnancy or breastfeeding.
  3. Rapidly progressive cognitive decline occurring over weeks or months, typically indicative of prion disease, neoplasia, or metabolic disorders.
  4. Subjects who require a legal guardian or tutor.

Exclusion Criteria (validation sub-study):

  1. Secondary forms of cognitive impairment based on medical history, neurological examination, and neuroimaging findings.
  2. Pregnancy.
  3. Rapidly progressive cognitive decline occurring over weeks or months, typically indicative of prion disease, neoplasia, or metabolic disorders.
  4. Subjects who are unable to give informed consent and require a legal guardian or tutor.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Main Study Cohort
2000 adult patients attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital with subjective or objective cognitive complaints of progressive and suspected neurodegenerative nature. All patients undergo annual blood sampling for 5 years in addition to standard clinical follow-up.
A blood sample is collected once per year for 5 years (additional procedure beyond standard clinical care) for measurement of plasma biomarkers including: Abeta40, Abeta42, Abeta42/Abeta40 ratio, pTau-181, NfL, ApoE, ApoE4, GFAP, sTREM2, and other plasma neurodegeneration biomarkers. Blood draw is a routine clinical procedure with no specific contraindications. The only possible side effect is local hematoma at the puncture site. Plasma biomarker measurement is performed using a CE-marked medical device (Fujirebio, provided on free loan). Results do not modify the patient's standard diagnostic and therapeutic pathway.
Validation Sub-study Cohort
150 patients from the main cohort who undergo lumbar puncture as part of their routine diagnostic workup and have CSF biomarkers for Alzheimer's disease available within 6 months of blood draw. Only those with CSF biomarkers confirming a biological diagnosis of Alzheimer's disease continue longitudinal follow-up in the sub-study.
A blood sample is collected once per year for 5 years (additional procedure beyond standard clinical care) for measurement of plasma biomarkers including: Abeta40, Abeta42, Abeta42/Abeta40 ratio, pTau-181, NfL, ApoE, ApoE4, GFAP, sTREM2, and other plasma neurodegeneration biomarkers. Blood draw is a routine clinical procedure with no specific contraindications. The only possible side effect is local hematoma at the puncture site. Plasma biomarker measurement is performed using a CE-marked medical device (Fujirebio, provided on free loan). Results do not modify the patient's standard diagnostic and therapeutic pathway.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Time to progression to all-cause dementia in MCI patients (primary prognostic endpoint)
Tijdsspanne: Annually from baseline up to 5 years
Time to clinical progression to all-cause dementia in patients with Mild Cognitive Impairment (MCI) at baseline, assessed using multivariable Cox proportional hazards models. For each plasma biomarker, patients are divided into two groups (above/below the median) and compared using the log-rank test (cause-specific hazard). The study has greater than 95% power to detect a Hazard Ratio of 2 and approximately 75-80% power for HR of 1.5.
Annually from baseline up to 5 years

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in MMSE score over time
Tijdsspanne: Annually from baseline up to 5 years
Change over time in Mini-Mental State Examination (MMSE) score as a measure of cognitive progression. A decrease of 5 or more points is considered clinically significant progression of cognitive impairment due to AD.
Annually from baseline up to 5 years
Conversion from MCI to Alzheimer's disease dementia
Tijdsspanne: Annually from baseline up to 5 years
Rate of clinical conversion from Mild Cognitive Impairment (MCI) to Alzheimer's disease dementia over the 5-year follow-up period, assessed at each annual visit.
Annually from baseline up to 5 years
Longitudinal change in plasma Abeta42/Abeta40 ratio
Tijdsspanne: Annually from baseline up to 5 years
Change over time in the plasma Abeta42/Abeta40 ratio, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Annually from baseline up to 5 years
Longitudinal change in plasma pTau-181 levels
Tijdsspanne: Annually from baseline up to 5 years
Change over time in plasma phosphorylated tau 181 (pTau-181) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Annually from baseline up to 5 years
Longitudinal change in plasma NfL levels
Tijdsspanne: Annually from baseline up to 5 years
Change over time in plasma neurofilament light chain (NfL) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Annually from baseline up to 5 years
Longitudinal change in plasma GFAP levels
Tijdsspanne: Annually from baseline up to 5 years
Change over time in plasma Glial Fibrillary Acidic Protein (GFAP) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Annually from baseline up to 5 years
Longitudinal change in plasma sTREM2 levels
Tijdsspanne: Annually from baseline up to 5 years
Change over time in plasma soluble Triggering Receptor Expressed on Myeloid cells 2 (sTREM2) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Annually from baseline up to 5 years
Longitudinal change in plasma Abeta40 levels
Tijdsspanne: Annually from baseline up to 5 years
Change over time in plasma beta-amyloid 40 (Abeta40) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Annually from baseline up to 5 years
Longitudinal change in plasma Abeta42 levels
Tijdsspanne: Annually from baseline up to 5 years
Change over time in plasma beta-amyloid 42 (Abeta42) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Annually from baseline up to 5 years

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Diagnostic accuracy of plasma Abeta42/Abeta40 ratio vs CSF gold standard (sub-study)
Tijdsspanne: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Area under the ROC curve (AUC), sensitivity, and specificity of plasma Abeta42/Abeta40 ratio in diagnosing Alzheimer's disease, using CSF biomarkers (CSF-Abeta40, CSF-Abeta42, CSF-pTau, CSF-NfL) as the gold standard. Patients are classified as AD or non-AD based on CSF results. An AUC of at least 0.80 is expected, with greater than 95% power to reject H0: AUC=0.50 at alpha=0.05.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Diagnostic accuracy of plasma pTau-181 vs CSF gold standard (sub-study)
Tijdsspanne: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Area under the ROC curve (AUC), sensitivity, and specificity of plasma pTau-181 in diagnosing Alzheimer's disease, using CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Diagnostic accuracy of plasma NfL vs CSF gold standard (sub-study)
Tijdsspanne: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Area under the ROC curve (AUC), sensitivity, and specificity of plasma NfL in diagnosing Alzheimer's disease, using CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Diagnostic accuracy of plasma GFAP vs CSF gold standard (sub-study)
Tijdsspanne: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Area under the ROC curve (AUC), sensitivity, and specificity of plasma GFAP in diagnosing Alzheimer's disease, using CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma Abeta40 vs CSF gold standard (sub-study)
Tijdsspanne: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for Abeta40 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma Abeta42 vs CSF gold standard (sub-study)
Tijdsspanne: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for Abeta42 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma Abeta42/Abeta40 ratio vs CSF gold standard (sub-study)
Tijdsspanne: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for Abeta42/Abeta40 ratio biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma pTau-181 vs CSF gold standard (sub-study)
Tijdsspanne: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for pTau-181 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma NfL vs CSF gold standard (sub-study)
Tijdsspanne: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for NfL biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma GFAP vs CSF gold standard (sub-study)
Tijdsspanne: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for GFAP biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma sTREM2 vs CSF gold standard (sub-study)
Tijdsspanne: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for sTREM2 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma ApoE vs CSF gold standard (sub-study)
Tijdsspanne: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for ApoE biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma ApoE4 vs CSF gold standard (sub-study)
Tijdsspanne: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for ApoE4 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Hoofdonderzoeker: Massimo Filippi, Prof, MD, IRCCS San Raffaele

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

12 september 2023

Primaire voltooiing (Geschat)

1 juni 2032

Studie voltooiing (Geschat)

1 juni 2032

Studieregistratiedata

Eerst ingediend

16 juli 2026

Eerst ingediend dat voldeed aan de QC-criteria

16 juli 2026

Eerst geplaatst (Werkelijk)

21 juli 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

21 juli 2026

Laatste update ingediend die voldeed aan QC-criteria

16 juli 2026

Laatst geverifieerd

1 juli 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • BLAD

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .